Subcutaneous Infusions

08/01/2006 - "Also described are ways in which it may help to reduce the chance of accidental error when setting up and monitoring the delivery of 24-hour subcutaneous infusions for pain and symptom control."
05/01/2006 - "Subcutaneous infusion-site pain was the most frequently reported side effect, with one subject withdrawing from the study as a result. "
01/01/2021 - "However, pain at the subcutaneous infusion site, an expected side effect of this therapy, is often a deterrent to its widespread use. "
11/10/2020 - "Continuous subcutaneous infusion (CSCI) via ambulatory infusion pump (AIP) is a valuable method of pain control in palliative care. "
11/10/2020 - "Continuous subcutaneous infusion for pain control in dying patients: experiences from a tertiary palliative care center."

07/01/2005 - "Efficacy of continuous subcutaneous infusion in patients with cancer pain."
04/01/2002 - "With the minimal toxicity reported in this and previous studies, subcutaneous infusion of M6G may potentially provide clinically useful analgesia for advanced cancer pain. "
09/18/1991 - "Subcutaneous infusions for cancer pain."
03/01/1990 - "Continuous subcutaneous infusion of narcotics represents an alternate approach to pain management which can be effective in the management of cancer pain."
03/15/1992 - "Continuous subcutaneous infusion of opioid drugs with the use of a portable programmable pump is safe and effective in selected patients who have failed to respond to standard medical treatment of their cancer pain. "

01/01/2021 - "In the current work, prolonged systemic delivery of apomorphine via buccal mucosa was shown to be a promising treatment for Parkinson's disease as a substitute for clinically utilized subcutaneous infusions. "
12/01/2013 - "Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson's disease."
12/01/2013 - "Subcutaneous infusion of apomorphine is a useful treatment for motor and nonmotor complications in Parkinson's disease patients and improves the patient's quality of life. "
01/01/2018 - "Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial."
01/01/2011 - "Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect."

11/25/2022 - "In a randomized, placebo-controlled, double-blind, crossover study, 20 men with type 1 diabetes underwent a 6-day continuous subcutaneous infusion with GIP (6 pmol/kg/min) and placebo (saline), with an interposed 7-day washout period. "
03/01/1982 - "The use of portable devices for the subcutaneous infusion of insulin may facilitate the attainment of improved glycemic control in selected patients with insulin-dependent diabetes mellitus. "
04/01/2020 - "Evaluation of Glycaemic Control, Glucose Variability and Hypoglycaemia on Long-Term Continuous Subcutaneous Infusion vs. Multiple Daily Injections: Observational Study in Pregnancies With Pre-Existing Type 1 Diabetes."
09/01/2015 - "We investigated whether in young children with inadequately controlled type 1 diabetes and technical problems with continuous subcutaneous infusion of insulin at 100 units/mL the switch to insulin diluted to 10 units/mL (U10) can limit technical problems and improve glycemic control. "
05/01/2012 - "Continuous subcutaneous infusion of insulin lispro in children and adolescents with type 1 diabetes mellitus."

12/01/2011 - "Data on the total dose received in the last 24 h of life PRN and the last dose prescribed for administration via continuous subcutaneous infusion (CSCI) for agitation and restlessness were submitted. "
02/01/1993 - "It has proved effective in controlling terminal agitation, confusion, restlessness, dystonia and fitting in adults and can be given by subcutaneous infusion in combination with other drugs. "
08/01/1990 - "Midazolam by subcutaneous infusion is a well-tolerated, safe and effective treatment for terminal restlessness and agitation, and deserves more extensive evaluation."
08/01/1990 - "This article describes the use of a subcutaneous infusion of midazolam to control restlessness and agitation in 23 patients during the final stages of advanced cancer. "
07/01/1992 - "Sublingual lorazepam and continuous subcutaneous infusion of midazolam can be effective in controlling terminal restlessness."